Tamibarotene

Tamibarotene
Names
	Preferred IUPAC name 4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbamoyl]benzoic acid
Identifiers
CAS Number	94497-51-5;
3D model (JSmol)	Interactive image;
Beilstein Reference	3564473
ChEBI	CHEBI:32181;
ChEMBL	ChEMBL25202;
ChemSpider	97231;
DrugBank	DB04942;
IUPHAR/BPS	2648;
KEGG	D01418;
PubChem CID	108143;
UNII	08V52GZ3H9 ;
CompTox Dashboard (EPA)	DTXSID5046853 ;
	InChI InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26);
	SMILES O=C(O)c1ccc(cc1)C(=O)Nc2ccc3c(c2)C(CCC3(C)C)(C)C;
Properties
Chemical formula	C22H25NO3
Molar mass	351.446 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Tamibarotene (brand name: Amnolake), also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity against acute promyelocytic leukaemia (APL) . It is currently marketed only in Japan and early trials have demonstrated that it tends to be better tolerated than ATRA. It has also been investigated as a possible treatment for Alzheimer's disease, multiple myeloma and Crohn's disease. Tamibarotene is found to have inhibitory potential for the viral spike protein of Omicron variant of SARS-CoV2 and can be a potential candidate for developing potential therapeutics for the treatment of omicron variant of COVID19.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.